Jonathan Van Ness reveals using weight-loss medication to manage binge-eating disorder struggles

Jonathan Van Ness shares he's on weight-loss medication, crediting it with helping manage his binge-eating disorder.


Pop Culture & Art January 09, 2025
Jonathan Van Ness reveals using weight-loss medication to manage binge-eating disorder struggles

Jonathan Van Ness, known for his role on Queer Eye, recently shared that he is using GLP-1 weight-loss medication to help manage his binge-eating disorder. In a TikTok video posted on January 8, 2025, Van Ness opened up about his struggles with compulsive eating and the impact it had on his physical and mental health.

@jvn_official

TW: Weight & ED 🫶 Hey y’all, I’m opening up about GLP-1 use and learning a lot along the way @Getting Curious Podcast

♬ original sound - JVN

Van Ness, 37, explained that he started experiencing extreme weight fluctuations earlier this year, prompting him to seek medical advice. After consulting his healthcare provider, he began using the medication in September. He credited it with helping him feel a sense of control over his eating habits for the first time. “It’s been life-changing,” he shared in the video, emphasizing that seeking medical help was a crucial step in his journey toward better health.

The TV personality also acknowledged the stigma surrounding weight-loss medications, encouraging others to focus on their personal health needs rather than societal expectations. Van Ness emphasized that everyone's health journey is unique and that seeking professional guidance can be empowering.

Van Ness plans to explore the topic further on his podcast, Getting Curious with Jonathan Van Ness, where he will discuss his experiences and insights into managing binge-eating disorder. He expressed hope that sharing his story would inspire others to seek help and address their struggles without shame.

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ